L
Lytix Biopharma AS
F:6BG
Lytix Biopharma AS
F:6BG
Price:
0.926
EUR
0.65%
Market Closed
Market Cap:
€563.6k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Lytix Biopharma AS
F:6BG
|
NO |
|
D
|
Dof Group ASA
OSE:DOFG
|
NO |
|
Chunghwa Telecom Co Ltd
TWSE:2412
|
TW |
|
Colas SA
PAR:RE
|
FR |
|
K
|
Kwung's Holdings Ltd
HKEX:1925
|
CN |
|
Apollo Medical Holdings Inc
NASDAQ:ASTH
|
US |
|
S
|
Societe Generale SA
F:SGE
|
FR |
|
Australian Gold and Copper Ltd
ASX:AGC
|
AU |
|
I
|
Intelicanna Ltd
TASE:INTL
|
IL |
|
H
|
Healthcare Co Ltd
SSE:603313
|
CN |
|
Hot Chili Ltd
ASX:HCH
|
AU |
|
S
|
Studio Dragon Corp
KOSDAQ:253450
|
KR |
|
N
|
New Century Logistics (BVI) Ltd
NASDAQ:NCEW
|
HK |
|
Woodside Energy Group Ltd
ASX:WDS
|
AU |
|
Insurance Australia Group Ltd
ASX:IAG
|
AU |
|
Dril-Quip Inc
NYSE:DRQ
|
US |
|
REC Limited
BSE:532955
|
IN |
|
K
|
Karelia Tobacco Company Inc
ATHEX:KARE
|
GR |
|
A
|
Alto Neuroscience Inc
NYSE:ANRO
|
US |
|
Coeur Mining Inc
NYSE:CDE
|
US |
|
Buckle Inc
NYSE:BKE
|
US |
|
B
|
Babcock International Group PLC
OTC:BCKIY
|
UK |
|
Q
|
QES Group Bhd
KLSE:QES
|
MY |
|
S
|
Shinyoung Wacoal Inc
KRX:005800
|
KR |
Multiples-Based Value
The Multiples-Based Value for Lytix Biopharma AS (6BG) under the Base Case is hidden EUR. Compared with the current market price of 0.926 EUR, the stock appears hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
6BG Multiples-Based Value
LOCKED
Multiples Across Competitors
6BG Competitors Multiples
Lytix Biopharma AS Competitors
Lytix Biopharma AS Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
L
|
Lytix Biopharma AS
F:6BG
|
799.8m EUR | 1 341.4 | -11.2 | -10.1 | -10 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.1B USD | 6.2 | 90.8 | 15 | 20.8 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
362.4B USD | 111.6 | -1 741.9 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.1B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 9.5 | 28.7 | 21.6 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.2B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3.1 | 34 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
